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The degree to which patient care is concordant with 
guidelines is widely used to assess the quality of health 
care. Compliance with guidelines is very high for certain 
cancers and procedures but not for others. For example, 
patients with stage I-III colon cancer routinely undergo 
bowel resection, with very little variation in rates between 
regions or institutions (1). However, assuming that 
noncompliance to follow guidelines reflects a failure of 
the care providers is not so straightforward when there are 
many possible treatment alternatives that have very different 
characteristics, especially when there is controversy 
about whether they are equivalent. About 15% to 30% 
of patients with early-stage breast cancer who undergo 
breast-conservation surgery (BCS) do not receive whole-
breast irradiation (WBI), which has been the “standard” 
treatment for decades. Possible alternative radiations 
include accelerated partial breast irradiation (APBI) 
using brachytherapy or external-beam irradiation and 
intraoperative radiotherapy (IORT) (2-5), in which a single 
dose is given at the time of surgery. These two approaches 
substantially shorten the duration and inconvenience of 
radiation therapy. Traditional WBI requires patients to 
commit to a 5-7-week course of treatment, while APBI 
involves once or twice-daily treatments generally given over 
1-2 weeks and IORT requires no commitment beyond that 
the patient already has made to receiving surgery.
These alternatives to WBI have become increasingly 
popular over time. We identified 53,766 female breast 
cancer patients in the SEER-Medicare linked database age 
65 years or older diagnosed with a first breast cancer that 
was American Joint Committee on Cancer (AJCC) stage 
0, I, or II during 2002 and 2007. We limited the analysis 
to those most likely to have complete claims and excluded 
patients over age 70 with estrogen or progesterone-receptor 
positive node-negative cancers 2 cm or smaller. We found 
that the use of APBI (either brachytherapy or external-
beam radiation) increased dramatically in the study period, 
from 2% to 13% (Figure 1). Conversely, traditional WBI 
treatment decreased substantially, from 83% to 70%. 
Of note, the rate of BCS without any form of radiation 
increased slightly, showing that the advent of this more 
convenient technology did not result in an overall increase 
in the use of any radiation modality following BCS in this 
population but was rather substituting for WBI.
There were certainly no data during this time from 
randomized trials showing APBI had equal long-term 
effectiveness or toxicity to WBI and only limited single-
institution studies of this approach (6). There are also now 
long-term data from at least one randomized trial showing 
APBI may be equally as effective and safe as WBI (7). 
Insurance obstacles to the use of APBI have been removed 
since the era of our study, and the increasing use of external-
beam APBI makes it much more widely available than it 
was then. However, our study predicts that APBI will not 
reduce the proportion of the Medicare population that does 
not receive radiation at all.
Whether increasing the proportion of patients 
receiving radiation therapy is a good or bad thing is not 
so straightforward. It is inevitable that quality guidelines 
will lag behind changing community standards and the 
evidence base. Changing guidelines frequently is not 
easy organizationally, however. Another problem is how 
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guidelines deal with subgroups. It is clear that not all 
patients benefit equally from radiation therapy, particularly 
those with ductal carcinoma in situ or elderly patients 
with selected invasive cancers. For example, a randomized 
trial comparing tamoxifen alone to WBI plus tamoxifen 
following lumpectomy for women age 70 or older with 
estrogen receptor-positive tumors 2 cm or smaller with 
negative axillary nodes showed the 10-year breast relapse 
rates in the two arms to be 10% and 2%, respectively, with 
no differences in the ultimate rate of metastases, breast 
cancer-specific mortality, or overall mortality (8). Guidelines 
that are overly broad can therefore result in unnecessary or 
inappropriate treatment.
But finally, and most difficult of all, how should guidelines 
accommodate patients’ values and wishes? Patients choose 
treatments after comparing the costs and benefits of each 
alternative in consultation with their physicians. Suppose 
a patient is willing to accept a smaller long-term chance 
of cure in return for less immediate toxicity? In a classic 
article, McNeil and colleagues interviewed 14 patients 
with operable lung cancer, whom they asked to choose 
between two treatments: surgery, which had some risk of 
postoperative mortality but a higher 5-year survival rate; 
and radiotherapy, which had no immediate mortality but 
a lower 5-year survival rate. Many patients were averse to 
taking a risk of immediate death in order to have a greater 
chance of survival in the more distant future (9). From the 
perspective of a rational patient, treatment is acceptable 
only if there is a positive net benefit—but different patients 
make that calculation in different ways. What if the values 
of the members of the committee that created the guideline 
are not those of the patient? Then following the guidelines 
does a disservice to that person and is morally untenable for 
the physician.
In summary, guidelines may help clinicians make clinical 
practice more uniform and avoid over- or under-treatment. 
More population-based comparative effectiveness 
research is needed to help physicians make evidence-based 
decisions about the most appropriate care. Removing 
institutional, logistical, and financial obstacles to giving 
guideline-compliant care is important but may not reduce 
noncompliance much when the recommended treatments 
have significant potential side effects or even inconvenience. 
Further, guidelines rarely take patient wishes into account 
beyond certain points (e.g., whether the patient would 
rather have mastectomy or breast-conservation therapy). It 
is easier to measure whether particular treatments have or 
have not been done according to a guideline than to assess 
whether the patient’s values have been served. Nonetheless, 
some ways exist to help patients come to an informed 
decision when treatment options have different costs and 
benefits (10).
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